Eloxx doses first patients in Alport syndrome trial, clears IND for ADPKD study
Eloxx reported Q3 2026 results with two rare kidney disease programs now advancing, $56.3 million in cash, and runway into 2028.
SEC filing
2 stories
Eloxx reported Q3 2026 results with two rare kidney disease programs now advancing, $56.3 million in cash, and runway into 2028.
SEC filing
Eloxx Pharmaceuticals expanded its board and named a new chief medical officer while detailing its global Phase 2 EXPRESS trial for exaluren in nonsense-mutation ADPKD.
SEC filing